Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

SARCLISA

ISATUXIMAB-IRFC

Standard Dose
500MG/25ML (20MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview SARCLISA is listed in Drugs@FDA under application 761113 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient ISATUXIMAB-IRFC Form and strength INJECTABLE;INJECTION - 500MG/25ML (20MG/ML) Sponsor SANOFI AVENTIS US Submission history Latest submission status date: 2024-10-25 00:00:00.

Structured Monograph

Clinical summary

Approval overview SARCLISA is listed in Drugs@FDA under application 761113 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient ISATUXIMAB-IRFC Form and strength INJECTABLE;INJECTION - 500MG/25ML (20MG/ML) Sponsor SANOFI AVENTIS US Submission history Latest submission status date: 2024-10-25 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.